HCWB is trading at $4.36 (5.7% down) as traders digest its recent 1-for-6 reverse stock split and Nasdaq bid-price compliance news.
- The stock has experienced significant volatility since the split became effective on June 30, 2026.
- Investors are currently reassessing the micro-cap biotech’s dilution risk and overall listing stability.
- The reverse split was a strategic move intended to regain compliance with Nasdaq's minimum bid price requirements.